Northwest Biotherapeutics (NBYB) Financial Statements

0 Followers

Northwest Biotherapeutics Financial Overview

Northwest Biotherapeutics's market cap is currently €248.76M. The company's EPS TTM is €-0.0249; its P/E ratio is -6.83; Northwest Biotherapeutics is scheduled to report earnings on ―, and the estimated EPS forecast is €―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Income Statement
Total Revenue	$ 1.38M	$ 1.38M	$ 1.93M	$ 1.68M	$ 1.00M
Gross Profit	$ -959.00K	$ 1.38M	$ -25.80M	$ 135.00K	$ -19.30M
Operating Income	$ -59.91M	$ -66.51M	$ -55.51M	$ -67.18M	$ -52.70M
EBITDA	$ -49.67M	$ -73.64M	$ -55.34M	$ -97.42M	$ 184.72M
Net Income	$ -61.48M	$ -83.78M	$ -62.60M	$ -105.03M	$ 179.13M
Balance Sheet
Cash & Short-Term Investments	$ 3.04M	$ 2.17M	$ 2.13M	$ 6.96M	$ 15.17M
Total Assets	$ 81.29M	$ 26.73M	$ 27.86M	$ 31.32M	$ 40.16M
Total Debt	$ 64.83M	$ 67.44M	$ 45.56M	$ 26.61M	$ 38.26M
Net Debt	$ 61.79M	$ 65.27M	$ 43.43M	$ 19.64M	$ 23.09M
Total Liabilities	$ 128.86M	$ 105.71M	$ 74.92M	$ 159.43M	$ 164.15M
Stockholders' Equity	$ -47.57M	$ -78.98M	$ -46.98M	$ -128.10M	$ -123.99M
Cash Flow
Free Cash Flow	$ -46.27M	$ -58.03M	$ -57.07M	$ -55.68M	$ -44.31M
Operating Cash Flow	$ -44.76M	$ -57.02M	$ -53.64M	$ -52.77M	$ -38.30M
Investing Cash Flow	$ -1.81M	$ -1.01M	$ -3.44M	$ -2.90M	$ -6.01M
Financing Cash Flow	$ 49.33M	$ 56.78M	$ 52.76M	$ 41.97M	$ 48.13M

Currency in USD

Northwest Biotherapeutics Earnings and Revenue History

Income Statement >

Northwest Biotherapeutics Debt to Assets

Balance Sheet >

Northwest Biotherapeutics Cash Flow

Cash Flow >

Northwest Biotherapeutics Forecast EPS vs Actual EPS

Earnings >